Overview

Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction

Status:
Enrolling by invitation

Trial end date:
2022-05-31

Target enrollment:

Participant gender:

Summary

This study is to assess LDL-C reductions at Week 24 and the mean of Weeks 22 and 24 with monthly Q4W (≤31 days) dosing of LIB003 300 mg administered subcutaneously (SC) compared to placebo in patients 18 years or older with Heterozygous FH on stable diet and oral LDL-C lowering drug therapy.

Phase:

Phase 3

Details

Lead Sponsor:

LIB Therapeutics LLC

Collaborator:

Medpace, Inc.